Myriad Genetics
MYGN
195 hedge funds and large institutions have $1.13B invested in Myriad Genetics in 2022 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 72 increasing their positions, 66 reducing their positions, and 20 closing their positions.
2,953% more call options, than puts
Call options by funds: $1.31M | Put options by funds: $43K
40% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 20
2% more funds holding
Funds holding: 191 → 195 (+4)
9% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 66
4.78% less ownership
Funds ownership: 101.04% → 96.26% (-4.8%)
27% less capital invested
Capital invested by funds: $1.55B → $1.13B (-$423M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$37.3M |
| 2 |
GCM
Glenview Capital Management
New York
|
+$30.5M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$15.4M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$7.05M |
| 5 |
State Street
Boston,
Massachusetts
|
+$6.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EARNEST Partners
Atlanta,
Georgia
|
-$60.9M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$14.2M |
| 3 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$13.1M |
| 4 |
New York State Common Retirement Fund
Albany,
New York
|
-$12.6M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$8.52M |
MYGN Hedge Fund Activity: Q4 2022 in Review
195 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q4 2022, worth a combined $1.13B — down 27% from $1.55B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new MYGN positions and 20 closed out — a net gain of 8 holders — while 72 added to existing stakes and 66 trimmed.
The largest buyer was Camber Capital Management, adding an estimated $37.3M. The largest seller was EARNEST Partners, cutting an estimated $60.9M.
- 195 institutional investors held Myriad Genetics (MYGN) as of Q4 2022, up from 191 in Q3 2022.
- Funds reported $1.13B of Myriad Genetics stock for Q4 2022, down 27% quarter-over-quarter.
- 28 funds opened new Myriad Genetics positions in Q4 2022 and 20 closed out, a net change of +8 holders.
- The largest Myriad Genetics buyer in Q4 2022 was Camber Capital Management, an estimated $37.3M added.
- The largest Myriad Genetics seller in Q4 2022 was EARNEST Partners, an estimated $60.9M sold.
Based on aggregated 13F filings for Q4 2022.